[en] For clinical studies of sarcopenia and frailty, clinically meaningful outcome measures are needed to monitor disease progression, evaluate efficacy of interventions, and plan clinical trials. Physical performance measures including measures of gait speed and other aspects of mobility and strength have been used in many studies, although a definition of clinically meaningful change in performance has remained unclear. The International Conference on Frailty and Sarcopenia Research Task Force (ICFSR-TF), a group of academic and industry scientists investigating frailty and sarcopenia, met in Miami Beach, Florida, USA in February 2019 to explore approaches for establishing clinical meaningfulness in a manner aligned with regulatory authorities. They concluded that clinical meaningful change is contextually dependent, and that both anchor- based and distribution-based methods of quantifying physical function are informative and should be evaluated relative to patient-reported outcomes. In addition, they identified additional research needed to enable setting criteria for clinical meaningful change in trials.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Guralnik, Jack
Bandeen-Roche, Karen
Bhasin, Shalender A.R.
Eremenco, Sonya
Landi, Francesco
Muscedere, John
Perera, S.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Woodhouse, Linda
Vellas, Bruno
Language :
English
Title :
Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force.
World Health Organization. The International Classification of Functioning, Disability and Health (ICF). Geneva2001.
Jette AM. Toward a common language for function, disability, and health. Phys Ther 2006;86:726–734. DOI: 10.1093/ptj/86.5.726
Abellan van Kan G, Cameron Chumlea W, Gillette-Guyonet S, et al. Clinical trials on sarcopenia: methodological issues regarding phase 3 trials. Clin Geriatr Med 2011;27:471–482. DOI: 10.1016/j.cger.2011.03.010
Vellas B, Fielding R, Bhasin S, et al. Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 2016;5:194–200.
Vellas B, Pahor M, Manini T, et al. Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations. J Nutr Health Aging 2013;17:612–618. DOI: 10.1007/s12603-013-0362-7
Chiles Shaffer N, Fabbri E, Ferrucci L, Shardell M, Simonsick EM, Studenski S. Muscle Quality, Strength, and Lower Extremity Physical Performance in the Baltimore Longitudinal Study of Aging. J Frailty Aging 2017;6:183–187.
Pahor M, Manini T, Cesari M. Sarcopenia: clinical evaluation, biological markers and other evaluation tools. J Nutr Health Aging 2009;13:724–728. DOI: 10.1007/s12603-009-0204-9
Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc 2006;54:743–749. DOI: 10.1111/j.1532-5415.2006.00701.x
Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85–94. DOI: 10.1093/geronj/49.2.M85
Podsiadlo D, Richardson S. The Timed “Up & Go”: A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142–148. DOI: 10.1111/j.1532-5415.1991.tb01616.x
Cesari M, Fielding R, Benichou O, et al. Pharmacological Interventions in Frailty and Sarcopenia: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 2015;4:114–120.
Brach JS, Perera S, Studenski S, Katz M, Hall C, Verghese J. Meaningful change in measures of gait variability in older adults. Gait Posture 2010;31:175–179. DOI: 10.1016/j.gaitpost.2009.10.002
Oh-Park M, Perera S, Verghese J. Clinically meaningful change in stair negotiation performance in older adults. Gait Posture 2012;36:532–536. DOI: 10.1016/j.gaitpost.2012.05.015
Perera S, Studenski S, Chandler JM, Guralnik JM. Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival. J Gerontol A Biol Sci Med Sci 2005;60:894–900. DOI: 10.1093/gerona/60.7.894
Page P. Beyond statistical significance: clinical interpretation of rehabilitation research literature. Int J Sports Phys Ther 2014;9:726–736.
McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995;4:293–307. DOI: 10.1007/BF01593882
Perera S, Studenski S, Newman A, et al. Are estimates of meaningful decline in mobility performance consistent among clinically important subgroups? (Health ABC study). J Gerontol A Biol Sci Med Sci 2014;69:1260–1268. DOI: 10.1093/gerona/glu033
Kwon S, Perera S, Pahor M, et al. What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging 2009;13:538–544. DOI: 10.1007/s12603-009-0104-z
Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34–42. DOI: 10.1016/j.jclinepi.2006.03.012
Simonsick EM, Guralnik JM, Volpato S, Balfour J, Fried LP. Just get out the door! Importance of walking outside the home for maintaining mobility: findings from the women’s health and aging study. J Am Geriatr Soc 2005;53:198–203. DOI: 10.1111/j.1532-5415.2005.53103.x
Studenski S. What are the outcomes of treatment among patients with sarcopenia? J Nutr Health Aging 2009;13:733–736. DOI: 10.1007/s12603-009-0206-7
Finch E, Walsh M, Thomas SG, Woodhouse LJ. Functional ability perceived by individuals following total knee arthroplasty compared to age-matched individuals without knee disability. J Orthop Sports Phys Ther 1998;27:255–263. DOI: 10.2519/jospt.1998.27.4.255
Jones LW, Cohen RR, Mabe SK, et al. Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol 2009;94:79–85. DOI: 10.1007/s11060-009-9803-x
Stratford PW, Kennedy D, Pagura SM, Gollish JD. The relationship between self-report and performance-related measures: questioning the content validity of timed tests. Arthritis Rheum 2003;49:535–540. DOI: 10.1002/art.11196
Stratford PW, Kennedy DM, Woodhouse LJ. Performance measures provide assessments of pain and function in people with advanced osteoarthritis of the hip or knee. Phys Ther 2006;86:1489–1496. DOI: 10.2522/ptj.20060002
Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109–122. DOI: 10.1056/NEJMoa1000485
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–423. DOI: 10.1093/ageing/afq034
Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014;69:547–558. DOI: 10.1093/gerona/glu010
Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA 2016;316:722–733. DOI: 10.1001/jama.2016.11136
European Medicines Agency. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. In: (CHMP) CftMPfHU, ed. London2010.
Reginster JY, Reiter-Niesert S, Bruyere O, et al. Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis Cartilage 2015;23:2086–2093. DOI: 10.1016/j.joca.2015.07.001
Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis 2017;76:1537–1543. DOI: 10.1136/annrheumdis-2016-210860
Beaudart C, Biver E, Reginster JY, et al. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing 2015;44:960–966. DOI: 10.1093/ageing/afv133
Cosman F, Crittenden DB, Ferrari S, et al. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. J Bone Miner Res 2018;33:1219–1226. DOI: 10.1002/jbmr.3427
MacEwan JP, Gill TM, Johnson K, et al. Measuring Sarcopenia Severity in Older Adults and the Value of Effective Interventions. J Nutr Health Aging 2018;22:1253–1258. DOI: 10.1007/s12603-018-1104-7
McCloskey E, Johansson H, Harvey NC, et al. Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study. J Bone Miner Res 2018;33:1020–1026. DOI: 10.1002/jbmr.3411
